NCT00554918View on ClinicalTrials.gov

Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

June 30, 2013

Conditions
Metastatic CancerProstate Cancer
Interventions
DRUG

docetaxel

DRUG

prednisolone

DRUG

zoledronic acid

PROCEDURE

quality-of-life assessment

RADIATION

strontium chloride Sr 89

Trial Locations (16)

B15 2TH

Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham

GL53 7AN

Gloucestershire Oncology Centre at Cheltenham General Hospital, Cheltenham

GL1 3NN

Gloucestershire Royal Hospital, Gloucester

IP4 5PD

Ipswich Hospital, Ipswich

ME16 9QQ

Mid Kent Oncology Centre at Maidstone Hospital, Maidstone

M20 4BX

Christie Hospital, Manchester

SM2 5PT

Royal Marsden - Surrey, Sutton

WS2 9PS

Walsall Manor Hospital, Walsall

AB25 2ZN

Aberdeen Royal Infirmary, Aberdeen

KA6 6DX

Ayr Hospital, Ayr

EH4 2XU

Edinburgh Cancer Centre at Western General Hospital, Edinburgh

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

KA2 OBE

Crosshouse Hospital, Kilmarnock

ML2 0DP

Wishaw General Hospital, Wishaw

CF14 2TL

Velindre Cancer Center at Velindre Hospital, Cardiff

LL 18 5UJ

Glan Clwyd Hospital, Rhyl, Denbighshire

All Listed Sponsors
lead

University Hospital Birmingham

OTHER

NCT00554918 - Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy | Biotech Hunter | Biotech Hunter